febrile neutropenia. He received empiric antibiotics and antifungal medications, the neutropenia and fever resolved, and he was discharged. He did not require a nasal gastric tube or a PEG tube during treatment, and he went on to receive adjuvant
Search Results
Presenters: Jimmy J. Caudell, David G. Pfister, and Randal S. Weber
Presenter: Arlene O. Siefker-Radtke
govitecan may experience side effects. Neutropenia, including febrile neutropenia, and diarrhea, nausea, and vomiting were among the most frequently reported treatment-related adverse events in the study population. 10 “Patients with bladder cancer, in
Presenter: Alexander E. Perl
reduction from 300 to 200 mg. Febrile neutropenia is managed with antibiotics. There were no treatment-related deaths in the QUAZAR study. 6 The NCCN Guidelines do not have data on the use of FLT3 inhibitors posttransplant. Two randomized trials support
Zachary Veitch, Omar F. Khan, Derek Tilley, Patricia A. Tang, Domen Ribnikar, Douglas A. Stewart, Xanthoula Kostaras, Karen King, and Sasha Lupichuk
practices, Shayne et al 30 identified significant predictors of chemotherapy dose reduction, including BSA >2 m 2 , age ≥65 years, febrile neutropenia, and comorbidities (particularly renal disease). In other retrospective studies, obesity has been
Jacqueline N. Poston and Pamela S. Becker
the threshold for recommended use of growth factors in the NCCN Guidelines for MGFs. These guidelines suggest the use of growth factors for regimens that are associated with a high risk of febrile neutropenia (>20%) or an with intermediate risk (10
William G. Wierda, Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Paolo Caimi, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Richard T. Hoppe, Steven M. Horwitz, Mark S. Kaminski, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Michael G. Martin, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth Roberts, Ayman A. Saad, Erin D. Snyder, Lubomir Sokol, Lode J. Swinnen, Julie M. Vose, Joachim Yahalom, Mary A. Dwyer, and Hema Sundar
®. P <.001), PFS (not reached in the idelalisib group vs 5.5 months for placebo), and OS at 12 months (92% vs 80%; P =.02) compared with rituximab plus placebo. Grade 3 or 4 AEs (pneumonia, pyrexia, and febrile neutropenia) were reported in 40% of
Dawn Goetz
seen grade 3 or 4 adverse effects are neutropenia, febrile neutropenia, anemia, leukopenia, diarrhea, fatigue, and asthenia. The approximate neutrophil nadir is 12 days, and cabazitaxel carries a black box warning against giving the drug to patients
enrolled at dose level 1 (100 mg, qdx3, weekly), and 2 developed dose-limiting toxicities (DLTs). These DLTs included deep venous thrombosis/pulmonary embolism and grade IV febrile neutropenia in patient 1, and grade III febrile neutropenia and Clostridium
Elizabeth A. Griffiths, Laura M. Alwan, Kimo Bachiashvili, Anna Brown, Rita Cool, Peter Curtin, Mark B. Geyer, Ivana Gojo, Avyakta Kallam, Wajih Z. Kidwai, Dwight D. Kloth, Eric H. Kraut, Gary H. Lyman, Sudipto Mukherjee, Lia E. Perez, Rachel P. Rosovsky, Vivek Roy, Hope S. Rugo, Sumithira Vasu, Martha Wadleigh, Peter Westervelt, and Pamela S. Becker
resources page ( https://www.nccn.org/covid-19/pdf/HGF_COVID-19.pdf ). 13 We have compiled the following in-depth description of the rationale and evidence supporting our recommendations. Avoidance and Treatment of Neutropenia Febrile neutropenia
neutropenia (grade 3: 69%; grade 4: 29%), febrile neutropenia (8%), thrombocytopenia (37%), and anemia (25%). Seven patients experienced treatment-related serious AEs, with 1 grade 5 event. Of the evaluable patients, 80% and 7% achieved clinical complete and